2.1. Study Design
This triple-blind randomized controlled trial was conducted in three outpatient centers in Isfahan, Iran, between 5 December 2020 and 31 March 2021. This study was conducted following the Good Practice Guideline. The study protocol was approved by the Ethics Committee of the Isfahan University of Medical Sciences (IR.MUI.MED.REC.1399.780). Patients were informed about the study protocol and were asked to sign an informed consent before participation. The study protocol was registered in the Iranian Registry of Clinical Trials on 2 December 2020 (IRCT20171219037964N3). We follow the Consolidated Standards for Reporting Trials (CONSORT 2010) guideline in reporting the results [